Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 57

Sort by

Sort Order Select

Journal Articles

Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trial

Blood (2024) 144 (5): 541–551.

https://doi.org/10.1182/blood.2023023625

Published: 2024

Includes: Supplemental data

Journal Articles

Measurable Residual Disease Assessment in Patients with Acute Myeloid Leukemia Aged ≥60 Years Treated with a 10-Day Decitabine Schedule Versus Intensive Chemotherapy in the AML21 Study (NCT02172872)

Blood (2023) 142 (Supplement 1): 2948.

https://doi.org/10.1182/blood-2023-184851

Published: 2023

Journal Articles

10-Day Decitabine Versus Intensive Chemotherapy Followed By Transplantation in Fit AML Patients Aged ≥60 Years: Health-Related Quality of Life Outcomes of the Randomized Phase III Trial AML21 of the EORTC Leukemia Group, Gimema, Celg, and Gmds-SG

Blood (2022) 140 (Supplement 1): 1281–1283.

https://doi.org/10.1182/blood-2022-166544

Published: 2022

Journal Articles

Fertility Status Among Long-Term Childhood Acute Lymphoblastic Leukemia Survivors Enrolled between 1971 and 1998 in the EORTC Children Leukemia Group Trials 58741, 58831/2 and 58881

Blood (2017) 130 (Supplement 1): 2563.

https://doi.org/10.1182/blood.V130.Suppl_1.2563.2563

Published: 2017

Journal Articles

Socioeconomic Outcomes Among Long-Term Childhood Acute Lymphoblastic Leukemia Survivors Enrolled between 1971 and 1998 in the EORTC Children Leukemia Group Trials 58741, 58831/2 and 58881

Blood (2017) 130 (Supplement 1): 2191.

https://doi.org/10.1182/blood.V130.Suppl_1.2191.2191

Published: 2017

Journal Articles

Impact of the Type of Anthracycline and of Allogeneic Stem Cell Transplantation in the Treatment of Younger Acute Myeloid Leukemia Patients: Long-Term Follow-up of the EORTC-Gimema AML-10 Trial

Blood (2017) 130 (Supplement 1): 3850.

https://doi.org/10.1182/blood.V130.Suppl_1.3850.3850

Published: 2017

Journal Articles

Fetal Hemoglobin (HbF) Induction during Initial Decitabine (DAC) Treatment of Elderly High-Risk MDS and AML Patients: A Potential Dynamic Biomarker for Outcome

Julia Stomper, Gabriele Ihorst, Stefan Suciu, Philipp Nikolaus Sander, Heiko Becker, P.W. Wijermans, Emmanuel Bissé, Rainer Claus, Michael Lübbert

Blood (2017) 130 (Supplement 1): 4261.

https://doi.org/10.1182/blood.V130.Suppl_1.4261.4261

Published: 2017

Journal Articles

The Impact of Cytogenetic Clonality on Outcomes in Younger Acute Myeloid Leukemia Patients: Results on 1290 Patients Included in the EORTC/Gimema AML-10 and AML-12 Trials

Blood (2017) 130 (Supplement 1): 1385.

https://doi.org/10.1182/blood.V130.Suppl_1.1385.1385

Published: 2017

Journal Articles

Impact of Age and Treatment Group in Childhood High Hyperdiploid Low Risk B-Cell Acute Lymphoblastic Leukemia (ALL): Results of the CLG-EORTC 58951 Study

Blood (2016) 128 (22): 1743.

https://doi.org/10.1182/blood.V128.22.1743.1743

Published: 2016

Journal Articles

Elevated Pre-Treatment Fetal Hemoglobin Predicts Better Outcome in MDS/AML Patients Receiving 5-Aza-2'-Deoxycytidine (DAC)

Rainer Claus, MD, Gabriele Ihorst, PhD, Philipp Sander, Ljudmila Bogatyreva, Heiko Becker, MD, Pierre W Wijermans, MD, Stefan Suciu, Emmanuel Bissé, MD PhD, Michael Lübbert, MD

Blood (2016) 128 (22): 3175.

https://doi.org/10.1182/blood.V128.22.3175.3175

Published: 2016

Journal Articles

Post-Remission Treatment with Autologous or Allogeneic Bone Marrow Transplantation or Intensive Chemotherapy in Younger AML Patients: Long-Term Follow-up Results of the EORTC/Gimema AML-8A Study

Blood (2016) 128 (22): 2288.

https://doi.org/10.1182/blood.V128.22.2288.2288

Published: 2016

Journal Articles

Impact of Induction Regimen and of Allogeneic Hematopoietic Cell Transplantation on the Outcome in Younger Adults Patients with Acute Myeloid Leukemia with a Monosomal Karyotype: Results from the EORTC/Gimema AML-10 and AML-12 Trials

Frederic Baron, MD PhD, Marian Stevens-Kroef, PhD, Giovanna Meloni, MD, Petra Muus, MD PhD, Jean-Pierre Marie, MD, Constantijn J.M. Halkes, MD PhD, Xavier Thomas, MD PhD, Radovan Vrhovac, MD PhD, Giorgina Specchia, MD, Francois Lefrere, Sr., MD, Simona Sica, Marco Mancini, MD, Adriano Venditti, MD, Anne Hagemeijer, MD, Joop H. Jansen, PhD, Sergio Amadori, MD, Theo de Witte, MD, Roelof Willemze, MD PhD, Stefan Suciu, PhD

Blood (2016) 128 (22): 2847.

https://doi.org/10.1182/blood.V128.22.2847.2847

Published: 2016

Journal Articles

Prophylactic CNS Therapy (with or without Radiation Therapy) in Medium-High Risk Acute Lymphoblastic Leukemia (ALL) Children: Long-Term Outcome Evaluation of the Randomized BFM-Oriented Trial 58832 (period 1983-1989) of the EORTC Children Leukemia Group

Blood (2016) 128 (22): 2775.

https://doi.org/10.1182/blood.V128.22.2775.2775

Published: 2016

Journal Articles

t(12;21)/ ETV6 - RUNX1 Confers a Specific Pattern of In Vivo Sensitivity to Treatments in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL): Results of the Randomized Trials 58881 and 58951 of the EORTC Children Leukemia Group

Blood (2015) 126 (23): 793.

https://doi.org/10.1182/blood.V126.23.793.793

Published: 2015

Journal Articles

Clofarabine in Combination with a Standard Remission Induction Regimen in Patients 18-60 Years Old with Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS): Combined Phase I/II Results of the EORTC/Gimema AML-14A Trial

Dominik L.D. Selleslag, MD, Stefan Suciu, Giovanna Meloni, MD, Petra Muus, MD PhD, Constantijn J.M. Halkes, MD PhD, Adriano Venditti, MD, Safaa M Ramadan, MD PhD, Hans Pruijt, MD PhD, Liv Meert, MSc, Marco Vignetti, MD, Jean-Pierre Marie, MD, Dominique Bron, MD PhD, Theo de Witte, MD, Sergio Amadori, MD, Roelof Willemze, MD PhD, Frederic Baron, MD PhD

Blood (2014) 124 (21): 3675.

https://doi.org/10.1182/blood.V124.21.3675.3675

Published: 2014

Journal Articles

Prognostic Relevance of CD200 /Btla Deletions in Pediatric Precursor-B Cell Acute Lymphoblastic Leukemia Treated According to the EORTC-CLG 58951 Protocol

Blood (2014) 124 (21): 2394.

https://doi.org/10.1182/blood.V124.21.2394.2394

Published: 2014

Journal Articles

Improved Overall Survival with Gemtuzumab Ozogamicin (GO) Compared with Best Supportive Care (BSC) in Elderly Patients with Untreated Acute Myeloid Leukemia (AML) Not Considered Fit for Intensive Chemotherapy: Final Results from the Randomized Phase III Study (AML-19) of the EORTC and Gimema Leukemia Groups

Blood (2014) 124 (21): 619.

https://doi.org/10.1182/blood.V124.21.619.619

Published: 2014

Journal Articles

Characterization of acute myeloid leukemia based on levels of global hydroxymethylation

Leonie I. Kroeze, Mariam G. Aslanyan, Arno van Rooij, Theresia N. Koorenhof-Scheele, Marion Massop, Thomas Carell, Jan B. Boezeman, Jean-Pierre Marie, Constantijn J. M. Halkes, Theo de Witte, Gerwin Huls, Stefan Suciu, Ron A. Wevers, Bert A. van der Reijden, Joop H. Jansen

Blood (2014) 124 (7): 1110–1118.

https://doi.org/10.1182/blood-2013-08-518514

Published: 2014

Includes: Supplemental data

Journal Articles

Low-Dose Decitabine Vs Best Supportive Care In Older Patients With AML and Low Blast Counts: Results Of a Subgroup Analysis Of The Randomized Phase III Study 06011 Of The EORTC Leukemia Cooperative Group and German MDS Study Group

Heiko Becker, MD, Stefan Suciu, PhD, Björn Rüter, MD, Uwe Platzbecker, MD, PhD, Aristoteles Giagounidis, MD, Dominik Selleslag, MD, Boris Labar, MD, PhD, Ulrich Germing, MD, Helmut R. Salih, MD, Petra Muus, MD, PhD, Karl-Heinz Pflüger, MD, Anne Hagemeijer, MD, PhD, Hans-Eckart Schaefer, MD, Frédéric Baron, MD, PhD, Arnold Ganser, MD, Carlo Aul, MD, Theo de Witte, MD, Pierre W. Wijermans, MD, Michael Lübbert, MD

Blood (2013) 122 (21): 1452.

https://doi.org/10.1182/blood.V122.21.1452.1452

Published: 2013

Journal Articles

Aberrant 5-Hydroxymethylcytosine Levels Correlate With Poor Overall Survival In Acute Myeloid Leukemia

Leonie I Kroeze, Mariam G Aslanyan, Arno van Rooij, Theresia N Koorenhof-Scheele, Marion Massop, Thomas Carell, Jan B Boezeman, Jean-Pierre Marie, MD, Constantijn J.M. Halkes, MD, PhD, Theo M. de Witte, MD, Gerwin Huls, Stefan Suciu, PhD, Ron Wevers, Bert A. van der Reijden, Joop H. Jansen, PhD

Blood (2013) 122 (21): 1261.

https://doi.org/10.1182/blood.V122.21.1261.1261

Published: 2013

NARROW

Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trial

Measurable Residual Disease Assessment in Patients with Acute Myeloid Leukemia Aged ≥60 Years Treated with a 10-Day Decitabine Schedule Versus Intensive Chemotherapy in the AML21 Study (NCT02172872)

10-Day Decitabine Versus Intensive Chemotherapy Followed By Transplantation in Fit AML Patients Aged ≥60 Years: Health-Related Quality of Life Outcomes of the Randomized Phase III Trial AML21 of the EORTC Leukemia Group, Gimema, Celg, and Gmds-SG

Fertility Status Among Long-Term Childhood Acute Lymphoblastic Leukemia Survivors Enrolled between 1971 and 1998 in the EORTC Children Leukemia Group Trials 58741, 58831/2 and 58881

Socioeconomic Outcomes Among Long-Term Childhood Acute Lymphoblastic Leukemia Survivors Enrolled between 1971 and 1998 in the EORTC Children Leukemia Group Trials 58741, 58831/2 and 58881

Impact of the Type of Anthracycline and of Allogeneic Stem Cell Transplantation in the Treatment of Younger Acute Myeloid Leukemia Patients: Long-Term Follow-up of the EORTC-Gimema AML-10 Trial

Fetal Hemoglobin (HbF) Induction during Initial Decitabine (DAC) Treatment of Elderly High-Risk MDS and AML Patients: A Potential Dynamic Biomarker for Outcome

The Impact of Cytogenetic Clonality on Outcomes in Younger Acute Myeloid Leukemia Patients: Results on 1290 Patients Included in the EORTC/Gimema AML-10 and AML-12 Trials

Impact of Age and Treatment Group in Childhood High Hyperdiploid Low Risk B-Cell Acute Lymphoblastic Leukemia (ALL): Results of the CLG-EORTC 58951 Study

Elevated Pre-Treatment Fetal Hemoglobin Predicts Better Outcome in MDS/AML Patients Receiving 5-Aza-2'-Deoxycytidine (DAC)

Post-Remission Treatment with Autologous or Allogeneic Bone Marrow Transplantation or Intensive Chemotherapy in Younger AML Patients: Long-Term Follow-up Results of the EORTC/Gimema AML-8A Study

Impact of Induction Regimen and of Allogeneic Hematopoietic Cell Transplantation on the Outcome in Younger Adults Patients with Acute Myeloid Leukemia with a Monosomal Karyotype: Results from the EORTC/Gimema AML-10 and AML-12 Trials

Prophylactic CNS Therapy (with or without Radiation Therapy) in Medium-High Risk Acute Lymphoblastic Leukemia (ALL) Children: Long-Term Outcome Evaluation of the Randomized BFM-Oriented Trial 58832 (period 1983-1989) of the EORTC Children Leukemia Group

t(12;21)/ ETV6 - RUNX1 Confers a Specific Pattern of In Vivo Sensitivity to Treatments in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL): Results of the Randomized Trials 58881 and 58951 of the EORTC Children Leukemia Group

Clofarabine in Combination with a Standard Remission Induction Regimen in Patients 18-60 Years Old with Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS): Combined Phase I/II Results of the EORTC/Gimema AML-14A Trial

Prognostic Relevance of CD200 /Btla Deletions in Pediatric Precursor-B Cell Acute Lymphoblastic Leukemia Treated According to the EORTC-CLG 58951 Protocol

Characterization of acute myeloid leukemia based on levels of global hydroxymethylation

Low-Dose Decitabine Vs Best Supportive Care In Older Patients With AML and Low Blast Counts: Results Of a Subgroup Analysis Of The Randomized Phase III Study 06011 Of The EORTC Leukemia Cooperative Group and German MDS Study Group

Aberrant 5-Hydroxymethylcytosine Levels Correlate With Poor Overall Survival In Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only